<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20191103045320N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-12-21</date_registration>
      <primary_sponsor>Kashan University of Medical Sciences</primary_sponsor>
      <public_title>Comparative study of the effect of TAP (Transverse Abdominis Plane) block and anesthesia infiltration site on postoperative pain in patients with unilateral inguinal hernia repair surgery</public_title>
      <acronym></acronym>
      <scientific_title>Comparative study of the effect of TAP (Transverse Abdominis Plane) block and anesthesia infiltration site on postoperative pain in patients with unilateral inguinal hernia repair surgery</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-02-11</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>63</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/60499</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: Simple random method
Randomization will be done by picking a piece of paper inside a glass by an operating room technologist with closed eyes , on the one third of the papers it is written that "Transverse Abdominis Plane block" and on the other one third it is written "local infiltration" , and on the rest of the one third it is written "control".</study_design>
      <phase>0 (exploratory trials)</phase>
      <hc_freetext>Postoperative pain.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: TAP (transverse abdominis plane) Block Group, in this group local anesthetic (20 cc Bupivacaine .25 percent) will be injected in the transverse abdominis plane which is the site of the passage of the C fibers of the pain via ultrasound technique. Intervention 2: Intervention group: Local anesthesia infiltration , in this group of the intervention local anesthetic (20 cc Bupivacaine .25 percent) will be injected in the surrounding site of the surgery wound. Intervention 3: Control group: No intervention method, such as the classic and routine method, in this group no intervention in the operating room setting for the control of the post operative pain will be done.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The data obtained from the comparison of the two methods of TAP block and infiltration in patients in comparison with the control group will be presented in the form of published text.

When:
After the implementation of the plan

To whom:
Vice Chancellor for University Research and researchers and project consultants.

Conditions:
The data is usable and valuable in any outcome.

Where to obtain:
Vice Chancellor for Research and Technology of Kashan University of Medical Sciences.

How to obtain:
Necessary coordination should be provided in the Research Council of Kashan University of Medical Sciences according to the approved laws.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mehdi Rajabi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Kashan Imam Hossein Square</address>
        <city>Kashan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3791194955</zip>
        <telephone>+98 31 5545 3216</telephone>
        <email>rajabim98@gmail.com</email>
        <affiliation>Kashan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mehdi Rajabi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Kashan Imam Hossein Square</address>
        <city>kashan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3791194955</zip>
        <telephone>+98 31 5545 3216</telephone>
        <email>rajabim98@gmail.com</email>
        <affiliation>Kashan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>No history of drug addiction
Patients with ASA grade one and two
Do not take any pain medications 24 hours before surgery
عدم سابقه حساسیت به بوپی واکائین
Complete informed consent</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>70 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G89.18</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other acute postprocedural pain</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: TAP (transverse abdominis plane) Block Group, in this group local anesthetic (20 cc Bupivacaine .25 percent) will be injected in the transverse abdominis plane which is the site of the passage of the C fibers of the pain via ultrasound technique</i_keyword>
      <i_keyword>Intervention group: Local anesthesia infiltration , in this group of the intervention local anesthetic (20 cc Bupivacaine .25 percent) will be injected in the surrounding site of the surgery wound</i_keyword>
      <i_keyword>Control group: No intervention method, such as the classic and routine method, in this group no intervention in the operating room setting for the control of the post operative pain will be done.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Score of severity of the post operation pain. Timepoint: Before surgery, after admission to the recovery ward, 15 minutes after staying in the recovery ward, after admission to the surgery ward. Method of measurement: Pain is a subjective outcome, so, we ask the patients about the pain and they will score from 1 to 10 (10 = most severe). Other indicators of the pain such as hypertension, tachycardia, ECG changes, sweating, lacrimation and mydriasis will be considered.</prim_outcome>
      <prim_outcome>Nausea and vomiting in the post operative period setting. Timepoint: Before surgery, after admission to the recovery ward, 15 minutes after staying in the recovery ward, after admission to the surgery ward. Method of measurement: Asking from the patient, observing patient situation.</prim_outcome>
      <prim_outcome>Opioid consumption in the 24 hours after operation. Timepoint: Before surgery, after admission to the recovery ward, 15 minutes after staying in the recovery ward, after admission to the surgery ward. Method of measurement: Recording of the total opioid consumption in the patient document and in a piece of paper near the head of the patient.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Postoperative pain (visceral pain). Timepoint: Two, four, six, twelve and twenty-four hours after surgery. Method of measurement: Visual analog scale.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Deputy of research and technology</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-10-27</approval_date>
        <contact_name>Ethics committee of the Kashan University of Medical Sciences</contact_name>
        <contact_address>Qutb Ravandi Boulevard Kashan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
